Capricor Therapeutics Signs Binding Term Sheet with Nippon Shinyaku for European Expansion and Commercialization of Deramiocel for the Treatment of Duchenne Muscular Dystrophy
PremiumPress ReleasesCapricor Therapeutics Signs Binding Term Sheet with Nippon Shinyaku for European Expansion and Commercialization of Deramiocel for the Treatment of Duchenne Muscular Dystrophy
17h ago
Capricor Therapeutics to Present at Upcoming Investor and Scientific Conferences
Premium
Press Releases
Capricor Therapeutics to Present at Upcoming Investor and Scientific Conferences
12d ago
Capricor Therapeutics reports Q2 EPS (35c), consensus (36c)
Premium
The Fly
Capricor Therapeutics reports Q2 EPS (35c), consensus (36c)
1M ago
Capricor Therapeutics Announces Long-Term Benefit of Deramiocel (CAP-1002) in Both Skeletal Muscle and Cardiac Function in the HOPE-2 OLE Study in Duchenne Muscular Dystrophy
PremiumPress ReleasesCapricor Therapeutics Announces Long-Term Benefit of Deramiocel (CAP-1002) in Both Skeletal Muscle and Cardiac Function in the HOPE-2 OLE Study in Duchenne Muscular Dystrophy
3M ago
Capricor announces three-year safety, efficacy results from HOPE-2 OLE study
Premium
The Fly
Capricor announces three-year safety, efficacy results from HOPE-2 OLE study
3M ago
CORRECTION: Capricor Therapeutics
Premium
Press Releases
CORRECTION: Capricor Therapeutics
3M ago
Capricor Therapeutics completes Type B meeting with FDA for CAP-1002 program
PremiumThe FlyCapricor Therapeutics completes Type B meeting with FDA for CAP-1002 program
3M ago
Capricor Therapeutics announces 3-year efficacy results from HOPE-2 OLE study
Premium
The Fly
Capricor Therapeutics announces 3-year efficacy results from HOPE-2 OLE study
4M ago
Capricor Therapeutics Announces Positive 3-Year Efficacy Results from HOPE-2 Open Label Extension Study of CAP-1002 in Duchenne Muscular Dystrophy
Premium
Press Releases
Capricor Therapeutics Announces Positive 3-Year Efficacy Results from HOPE-2 Open Label Extension Study of CAP-1002 in Duchenne Muscular Dystrophy
4M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100